MedTrace Logo

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

NCT06314698 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 478

Last updated 2024-03-18

No results posted yet for this study

Summary

The purpose of this study is to determine if narlumosbart is non-inferior to denosumab in the treatment of bone diseases from multiple myeloma (MM).

Conditions

Interventions

DRUG

Narlumosbart

Administered by subcutaneous injection once every 4 weeks.

DRUG

Denosumab

Administered by subcutaneous injection once every 4 weeks.

Sponsors & Collaborators

  • Shanghai JMT-Bio Inc.

    collaborator INDUSTRY

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Jian Hou, M.D. · RenJi Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2024-12-31
Completion
2027-04-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06314698 on ClinicalTrials.gov